Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06094634
Other study ID # 23-0256
Secondary ID R01AA030479
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 2024
Est. completion date July 2027

Study information

Verified date February 2024
Source University of North Carolina, Chapel Hill
Contact Teerada Sripaipan
Phone (919) 966 6236
Email teerada@email.unc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness of a brief alcohol intervention (BAI) vs. standard of care (SOC) to improve pre-exposure prophylaxis (PrEP) use among men who have sex with men (MSM) with unhealthy alcohol use initiating or re-initiating PrEP in Vietnam.


Description:

This is a two-arm effectiveness randomized controlled trial (RCT) to compare the brief alcohol intervention (BAI) to the standard of care (SOC) among MSM with unhealthy alcohol use who are initiating or reinitiating oral, event-driven, or injectable PrEP in Vietnam. The BAI draws from Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET) and Cognitive Behavioral Therapy (CBT) and includes 2 in-person sessions and 2 telephone sessions. Eligible participants (n=564) will be randomized 1:1 to each arm (282 per arm). Additional assessments among a subset of participants in the BAI arm will assess acceptability of the intervention (n=48) Study activities will span 5 years. Individual MSM participants will be followed-up for 12 months with assessment visits at 3, 6, 9, and 12 months after enrollment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 564
Est. completion date July 2027
Est. primary completion date July 2027
Accepts healthy volunteers No
Gender Male
Age group 16 Years and older
Eligibility Inclusion Criteria: - Newly initiating PrEP or re-initiating PrEP after at least 3 months from a missed PrEP appointment, based on Vietnamese PrEP guidelines - Assigned male sex at birth - Identify as male - Receptive or penetrative anal intercourse with a man in the past 6 months - AUDIT-C score = 4 (unhealthy alcohol use) - 16 years of age or older - Intention to receive PrEP care in Hanoi for 12 months - Willingness to provide informed consent Exclusion Criteria: - Psychological disturbance, cognitive impairment, or threatening behavior - Unwilling to provide locator information - Current participation in alcohol programs or studies - Current participation in other research studies (including HIV and PrEP studies) - Ever enrolled in an HIV vaccine study - Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA) = 10, indicating risk for alcohol withdrawal

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
The Brief Alcohol Intervention (BAI): Behavioral
The BAI draws from Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET) and Cognitive Behavioral Therapy (CBT) and comprises 2 in-person face-to-face sessions and 2 booster telephone sessions by a trained counselor.

Locations

Country Name City State
Vietnam Hanoi Medical University Hanoi

Sponsors (6)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill Hanoi Medical University, Johns Hopkins University, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), University of Washington

Country where clinical trial is conducted

Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary PrEP Persistence PrEP persistence is a measure of ongoing PrEP usage, defined as consistent presentation for care and refills. 12 months
Primary Heavy Drinking Days (Binge drinking) The number of days with =6 standard drinks of alcohol per occasion among the previous 30 days as assessed on the Timeline Followback. 12 months
Primary Incremental Cost-Effectiveness Ratio (ICER) The incremental cost-effectiveness ratio (ICER) is expressed as the incremental cost of the Brief Alcohol Intervention (BAI) per quality adjusted life-year (QALY) gained. ICER is defined as [Ci - Ca]/[Ei - Ea] with Ci and Ca being the respective costs of the BAI [i] and assessment only [a], and Ei and Ea the corresponding effectiveness. 12 months
Primary Acceptability of the brief alcohol intervention, as measured with mHIST Acceptability is an implementation-focused outcome and will be assessed using the Mental Health Implementation Science Tools (mhIST) Acceptability Scale for consumers, which consists of 15 items containing responses on a 4-point Likert scale. The mhIST score is calculated as the mean score of all responses ranging from 0-3. Higher mhIST scores indicate higher acceptability. 3 months
Primary Feasibility - proportion completed 4 sessions (intervention arm) Feasibility is an implementation-focused outcome and will be measured as the BAI completion rate among MSM. Three metrics will be considered, measured from the date of the first in-person session. The first metric will be the proportion of participants who completed all 4 sessions among those who were assigned to the intervention arm. 7 weeks
Primary Feasibility - proportion completed 2 sessions (intervention arm) Feasibility is an implementation-focused outcome and will be measured as the BAI completion rate among MSM. Three metrics will be considered, measured from the date of the first in-person session. The second metric will be the proportion of participants who completed at least 2 sessions among those who were assigned to the intervention arm. 7 weeks
Primary Feasibility - proportion completed 4 sessions (among initiators) Feasibility is an implementation-focused outcome and will be measured as the BAI completion rate among MSM. Three metrics will be considered, measured from the date of the first in-person session. The third metric will be the proportion of participants who completed at least 4 sessions among those who initiated at least one session. 7 weeks
Secondary PrEP Adherence PrEP adherence is a measure of pill-taking behavior and will be assessed by self-report and pharmacy records. Adherence will be assessed per person based on the type of PrEP prescribed but will be compared as a single measure.
Oral and event-driven PrEP adherence will be assessed as self-reported number of doses taken.
Oral PrEP adherence is defined with two thresholds: = 4 days/week, a threshold consistent with HIV prevention among MSM, and 7 days, indicating perfect adherence.
Event-driven PrEP adherence will be defined as completion of the 2+1+1 regimen for every reported anal or vaginal intercourse event.
Up to 12 months
Secondary Risk-aligned PrEP use Risk-aligned PrEP use is a measure of whether PrEP use is consistent with concurrent risk behavior. It is defined as persistent oral/injectable PrEP, event-driven PrEP (2+1+1), or clinician-supervised PrEP discontinuation.
More specifically, risk-aligned PrEP is defined as:
Persistent oral, event-driven or injectable PrEP,
Clinician-approved PrEP discontinuation.
Up to 12 months
Secondary Number of Drinking Days Number of drinking days is defined as the number of days with any alcohol use, among the previous 30 days as assessed on the Timeline Followback. The timeline followback will be administered at enrollment, 3 months and 12 months. Up to 12 months
Secondary Number of Drinks Per Drinking Day Drinks per drinking day is defined as the number of standard drinks of alcohol consumed on a drinking day, among the past 30 days as assessed on the Timeline Followback. The timeline followback will be administered at enrollment, 3 months and 12 months. Up to 12 months
Secondary Penetration Completion of at least one session among those assigned to the intervention arm. Up to 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT03411577 - Development and Testing of a Jamaican Mother-daughter HIV Risk-reduction Program N/A
Active, not recruiting NCT03112369 - Preventing HIV Among Native Americans Through the Treatment PTSD & Substance Use N/A
Not yet recruiting NCT03642314 - HIV Self-testing in Implementation PrEP Study N/A
Completed NCT01810315 - Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity Phase 1
Completed NCT00984971 - Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet Phase 1
Completed NCT00142935 - Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1 N/A
Active, not recruiting NCT03255915 - PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study) Early Phase 1
Completed NCT05037513 - Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky N/A
Recruiting NCT05087680 - An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South N/A
Recruiting NCT05804461 - Optimizing Pre-Exposure Prophylaxis (PrEP) Among Latino Men Who Have Sex With Men (MSM) in Puerto Rico N/A
Completed NCT03148171 - Project WERK (Wellness Encouragement Respect Kinship) N/A
Completed NCT04791007 - OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults Early Phase 1
Recruiting NCT05412433 - Clinic-based HIV Identification and Prevention Project Using Electronic Resources N/A
Active, not recruiting NCT03977181 - The Community PrEP Study to Assess the Acceptance of PrEP Delivered Through CBCT Platforms N/A
Recruiting NCT05165745 - Stick2PrEP Cisgender Women and Trans Individuals N/A
Completed NCT03719053 - Single Dose Truvada Study Phase 1
Recruiting NCT03856580 - Long-acting Biomedical HIV Prevention in Transgender Women N/A
Completed NCT02750540 - Optimization of a Tenofovir Enema for HIV Prevention Phase 1
Completed NCT01386294 - Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection Phase 3
Completed NCT00993811 - The Shang Ring: A Novel Male Circumcision Device for HIV Prevention Phase 1